# US 2024/0025930 A1 · Small molecule inhibitors selective for polo-like kinase protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0025930 A1
- Document ID: US20240025930A1
- Status: Published application
- Kind: A1
- Application number: 18/106,543
- Filed: 2023-02-07
- Published: 2024-01-25
- Earliest claimed: 2016-04-05
- Assignees: University of South Carolina
- Applicants: University of South Carolina
- Inventors: CAMPBELL MCINNES; SANDRA NAVONNE CRAIG
- Web page: https://patentgrep.com/patent/US20240025930A1

## CPC

- C07F 9/12: with hydroxyaryl compounds
- C07F 9/222: {Amides of phosphoric acids}
- A61P 35/00: Antineoplastic agents
- C07C 229/56: with amino and carboxyl groups bound in ortho-position
- C07C 233/66: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
- C07C 233/80: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C 233/81: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 235/56: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 235/84: with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 311/46: Y being a hydrogen or a carbon atom
- C07F 5/04: Esters of boric acids
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61P 35/04: specific for metastasis
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure of For instance, the inhibitors can include an alkyl benzamido benzoic acid core structure.

## Claims

### Claim 1

A method for inhibiting Polo-like Kinase proteins, the method comprising:
providing a small molecule PLK inhibitor to a medium containing one or more Polo-like Kinase proteins, wherein the small molecule PLK inhibitor has the general structure:
wherein
R1 comprises an alkyl, —O-alkyl, —S-alkyl, or —NH-alkyl, and optionally includes a terminal aryl;
R8 and R9 are independently hydrogen, alkyl, OH, NH2, SH, —S-alkyl, —O-alkyl, —NH-alkyl, —CONN-alkyl, halogen, or —CN;
X is an amide, —C1 to C4 alkyl-NH—, —NH—, —SNH—, —SONH—, or —SO2N—;
R7 is selected from the following structures:
a)
in which
R2 through R6 are independently selected from hydrogen, carboxyl, alkyl, alkyl ester, hydroxyl, methoxy, halogen, sulfonamide, phosphate, nitro, methylamine, or boronic acid, and
R10 is C or N, and R3 is relevant only when R10 is C;
b)
c)
d)
e)
f)
g)

### Claim 2 (depends on 1)

The method of claim 1, wherein the medium comprises a solution.

### Claim 3 (depends on 1)

The method of claim 1, wherein the medium comprises one or more cells.

### Claim 4 (depends on 3)

The method of claim 3, wherein the one or more cells comprise HeLa cervical cancer cells, PTEN-deficient prostate cancer (PC3) cells, KRAS mutant lung cancer (A-549) cells, or a combination thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the small molecule PLK inhibitor has the structure of one or more of:

### Claim 6 (depends on 1)

The method of claim 1, wherein the one or more Polo-like Kinase proteins comprise PLK3.

### Claim 7 (depends on 6)

The method of claim 6, wherein R1 comprises a C6 to C12 alkyl, R8 and R9 are hydrogen, R7 is a), R2 is hydrogen or carboxyl, R3 through R6 are independently selected from hydrogen, carboxyl, methyl, or hydroxyl, R10 is C, and X an amide linkage.

### Claim 8 (depends on 7)

The method of claim 7, wherein R1 comprises a C10 to C12 alkyl.

### Claim 9 (depends on 1)

The method of claim 1, wherein the small molecule PLK inhibitor has an atomic mass of about 1000 Daltons or less.

### Claim 10 (depends on 1)

The method of claim 1, wherein the small molecule PLK inhibitor has an atomic mass of about 500 Daltons or less.

### Claim 11 (depends on 1)

The method of claim 1, wherein the small molecule PLK inhibitor has a polar surface area of about 200 Å or less.

### Claim 12 (depends on 1)

The method of claim 1, wherein the small molecule PLK inhibitor has a polar surface area of about 100 Å or less.

### Claim 13 (depends on 1)

The method of claim 1, wherein the medium comprises one or more cells and the inhibitor induces apoptosis in a least a portion of the one or more cells.

### Claim 14 (depends on 1)

The method of claim 1, wherein the small molecule PLK inhibitor has the following structure:
wherein
R1 comprises an alkyl, —O-alkyl, —S-alkyl, or —NH-alkyl, and optionally includes a terminal aryl;
R2 through R6 are independently selected from hydrogen, carboxyl, alkyl, alkyl ester, hydroxyl, methoxy, halogen, sulfonamide, phosphate, nitro, methylamine, or boronic acid; and
X is an amide, —C1 to C4 alkyl-NH—, —NH—, —SNH—, —SONH—, or —SO2N—.

### Claim 15 (depends on 14)

The method of claim 14, wherein R1 is C3 to C8 alkyl and X is an amide.

### Claim 16 (depends on 1)

The method of claim 1, wherein the one or more Polo-like Kinase proteins comprise PLK1.

### Claim 17 (depends on 1)

The method of claim 1, wherein the small molecule PLK inhibitor has the following structure:
wherein
R1 comprises an alkyl, —O-alkyl, —S-alkyl, or —NH-alkyl, and optionally includes a terminal aryl;
R7 is selected from:
b)
c)
d)
e)
f)
g)
